PharmaKure and UiTM Team up To Research in Alzheimer's Disease

One of the most comprehensive universities in Malaysia, Universiti Teknologi MARA (UiTM), has signed a research cooperation agreement with PharmaKure, a clinical stage startup creating precision medicine for Alzheimer's disease and other neurological illnesses. Through academic-industry alliances, the partnership aims to further research activities on the application of machine learning methods to predict Alzheimer's disease using blood.

The new relationship aims to translate clinical research from UiTM using PharmaKure’s novel whole blood testing and machine learning technology for identifying early-stage Alzheimer’s disease to support the development of much needed diagnostic tests worldwide. Pharmakure recently announced a successful study for its proprietary ALZmetrix blood-based biomarker test, which together with its machine learning tools can predict which biomarkers are most useful in detecting people at high risk of developing Alzheimer’s disease, as per pharmabiz.

"The UK has an ageing population, where 1 in 14 people over the age of 65 have Alzheimer’s disease. There is an urgent need to not only identify people who will develop this devasting disease, but also develop treatments. This agreement marks a significant milestone in establishing a research collaboration with UiTM, a leading academic institute, allowing us to partner with key experts and enhance our in-house expertise in the analysis of molecular signatures of disease biomarkers associated with Alzheimer’s,” said Dr. Farid Khan, CEO of PharmaKure.

“Earlier and more accurate diagnostics for Alzheimer’s disease are desperately needed if we are to prevent this devastating disease before profound memory loss takes hold,” said Professor Andrew Doig, head of R&D at PharmaKure. “We are excited to be forming this relationship which will help us translate research from UiTM to further advance and commercialise diagnostic tests needed worldwide."